Neurocrine Biosciences (NASDAQ:NBIX) Director George Morrow Sells 7,200 Shares of Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Director George Morrow sold 7,200 shares of the company’s stock in a transaction on Tuesday, November 3rd. The shares were sold at an average price of $166.37, for a total value of $1,197,864.00. Following the completion of the sale, the director directly owned 10,386 shares in the company, valued at $1,727,918.82. This trade represents a 40.94% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Neurocrine Biosciences Stock Up 13.4%

Shares of NBIX stock opened at $164.85 on Wednesday. Neurocrine Biosciences, Inc. has a fifty-two week low of $122.14 and a fifty-two week high of $186.12. The stock has a market cap of $16.76 billion, a P/E ratio of 24.46, a P/E/G ratio of 0.64 and a beta of 0.36. The business has a fifty day simple moving average of $146.72 and a 200-day simple moving average of $147.60.

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings data on Monday, November 2nd. The company reported $3.29 EPS for the quarter, topping the consensus estimate of $1.91 by $1.38. The business had revenue of $1.12 billion for the quarter, compared to analyst estimates of $1.04 billion. Neurocrine Biosciences had a net margin of 18.98% and a return on equity of 24.11%. The business’s revenue for the quarter was up 41.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.04 EPS. On average, sell-side analysts anticipate that Neurocrine Biosciences, Inc. will post 7.72 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts have issued reports on NBIX shares. Truist Financial upped their price target on shares of Neurocrine Biosciences from $200.00 to $213.00 and gave the company a “buy” rating in a report on Monday, August 3rd. Wall Street Zen cut shares of Neurocrine Biosciences from a “buy” rating to a “hold” rating in a research note on Sunday, August 9th. Needham & Company LLC restated a “buy” rating and set a $204.00 price objective on shares of Neurocrine Biosciences in a research report on Friday, October 16th. Citigroup lifted their price objective on Neurocrine Biosciences from $249.00 to $253.00 and gave the stock a “buy” rating in a research report on Thursday, September 3rd. Finally, Wells Fargo & Company upped their target price on Neurocrine Biosciences from $175.00 to $200.00 and gave the company an “overweight” rating in a research note on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, Neurocrine Biosciences presently has an average rating of “Moderate Buy” and a consensus price target of $201.55.

Key Stories Impacting Neurocrine Biosciences

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Third-quarter revenue rose 41% year over year to $1.12 billion, exceeding estimates, while EPS of $3.29 also topped consensus. Product sales surpassed $1 billion for the first time. Neurocrine raised its 2026 INGREZZA net-sales outlook to $2.9–$2.925 billion, citing demand across its portfolio. Third-quarter results
• Positive Sentiment: Several analysts raised price targets after the results: Canaccord to $220, Piper Sandler to $215, RBC to $190, and Morgan Stanley to $185. Ratings ranged from buy/outperform to equal weight, so the target increases were broadly supportive but not uniformly bullish.
• Positive Sentiment: The company said it has begun a Phase 2 Alzheimer’s study and plans to present its neuroscience work and pipeline at the NEI Fall Congress. These updates add to investor focus on longer-term development opportunities, though the supplied reports provide limited study details. Alzheimer’s study and education update
• Negative Sentiment: Director George J. Morrow reported sales totaling 15,000 shares across transactions on November 2–3, in addition to a 300-share sale on October 30. The filings say the transactions were made under a pre-arranged Rule 10b5-1 plan, which may temper concern, and he retained 10,386 shares.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Candriam S.C.A. grew its holdings in shares of Neurocrine Biosciences by 32.2% during the 3rd quarter. Candriam S.C.A. now owns 344,883 shares of the company’s stock worth $49,097,000 after purchasing an additional 83,957 shares during the period. Ethic Inc. raised its holdings in Neurocrine Biosciences by 11.1% in the third quarter. Ethic Inc. now owns 1,909 shares of the company’s stock valued at $271,000 after buying an additional 191 shares during the period. Formidable Asset Management LLC purchased a new position in Neurocrine Biosciences in the third quarter valued at approximately $428,000. AlphaCentric Advisors LLC raised its holdings in Neurocrine Biosciences by 5.2% in the third quarter. AlphaCentric Advisors LLC now owns 10,230 shares of the company’s stock valued at $1,451,000 after buying an additional 503 shares during the period. Finally, Parallel Advisors LLC lifted its position in Neurocrine Biosciences by 3.5% during the third quarter. Parallel Advisors LLC now owns 1,780 shares of the company’s stock valued at $252,000 after buying an additional 61 shares in the last quarter. Institutional investors and hedge funds own 92.59% of the company’s stock.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc is a San Diego-based biopharmaceutical company focused on discovering, developing and commercializing medicines for neurological, neuroendocrine and psychiatric disorders. The company’s research programs target conditions in which treatments may address significant unmet medical needs.

Neurocrine’s leading product is INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor approved in the United States for the treatment of tardive dyskinesia and chorea associated with Huntington’s disease.